Journal of the American College of Nutrition · 2004 · 57 citations · 11 references
MedicinePharmacotherapyPsychiatryNeuropsychiatryPsychiatric PharmacotherapyPsychopharmacologyAntipsychotic PharmacologyAntipsychotic PharmacotherapyAntipsychotic TherapyPsychotic DisordersSchizophrenia PharmacotherapySchizophrenia Spectrum DisordersAcute Schizophrenia TreatmentAntipsychotic ActionAntipsychotic EfficacyAntipsychotic Medication UseControl Group DesignMatched Control GroupOral Antipsychotic TherapyPlasma Magnesium Regulation
OBJECTIVE: The aim of the study was the investigation of plasma magnesium, calcium, copper and zinc and erythrocyte magnesium levels in patients with paranoid schizophrenia and the influence of the therapy with two antipsychotic drugs (haloperidol and risperidone) on these concentrations. METHODS: We investigated the influence of treatment with haloperidol and risperidoneon plasma and erythrocyte magnesium and on plasmatic levels of zinc, calcium and copper on hospitalized 56 patients diagnosed with paranoid schizophrenia (DSM IV). RESULTS: Our data indicate a decrease of erythrocyte magnesium levels in schizophrenic patients (4.82 +/- 3.1 mg/L vs. 59.2 +/- 1.1 mg/L in control group, p < 0.01). The plasma level of magnesium was unchanged (18.9 +/- 2.17 mg/L in schizophrenic patients vs. 18.26 +/- 1.9 mg/L in control group). CONCLUSIONS: We consider plasma Cu(2+)/erythrocyte Mg(2+) and plasma Cu(2+)/Zn(2+) ratio two important biological markers of the acute paranoid schizophrenia.
11
Neuropsychological Aspects of Wilson's Disease
Jay K. Rathbun · International Journal of Neuroscience · 1996 · 93 citations
Medicine, Neurology, Psychiatry +16
Magnesium, Schizophrenia and Manic-Depressive Disease
George Kirov, K Tsachev · Neuropsychobiology · 2008 · 48 citations
Medicine, Pharmacology, Psychiatry +16
Magnesium deficiency in alcohol addiction and withdrawal.
Stanley R. Shane, Edmund B. Flink · PubMed · 1993 · 35 citations